SPOTLIGHT: Synta, GSK gain orphan drug designation


The FDA has granted its orphan drug designation to elesclomol, an investigational drug that treats metastatic melanoma. The drug is being advanced by a collaboration between Synta and GlaxoSmithKline. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.